Utility of Cytochrome P450 4F2 Genotyping to Assess Drug Interaction Risk for Brincidovovir, a Cytochrome P450 4F2 Substrate

Documenti analoghi

• Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic Modeling
  di: Swati Jaiswal, et al.
  Pubblicazione: (2025)
• Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates
  di: Ronilda D'Cunha, et al.
  Pubblicazione: (2026)
• A Phase 1 Study to Evaluate the Absorption, Metabolism, and Disposition of Dordaviprone in Healthy Adult Participants
  di: Yohannes Teffera, et al.
  Pubblicazione: (2025)
• A Drug–Drug Interaction Study of Mobocertinib and Midazolam, a Cytochrome P450 3A Substrate, in Patients With Advanced Non–Small Cell Lung Cancer
  di: Michael J. Hanley, et al.
  Pubblicazione: (2025)
• Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies
  di: Yingxue Chen, et al.
  Pubblicazione: (2025)